•  
  •  
 

Turkish Journal of Medical Sciences

Abstract

To validate patient responses to imatinib mesylate, which induces hematologic and cytogenetic remission and, consequently, modifies the progression of chronic myeloid leukemia (CML). Materials and methods: Between January 2006 and July 2009, 31 patients with chronic-phase CML were treated with imatinib therapy in the hematology unit of Atatürk University Medical Faculty Training Hospital. Imatinib treatment was begun at the standard dose of 400 mg/day, as either first-line or second-line therapy. Results: At the end of the second month of treatment, all of the patients had achieved complete hematologic response. After 12 months, the rate of complete cytogenetic response was 71%, and after 24 months, the rate of complete molecular response was 85%. The most commonly observed adverse event was edema (facial and/or peripheral). No grade 3 or 4 hematological adverse events were observed during the study period. Conclusion: Our CML patients' responses to imatinib therapy were similar to those seen in other countries, although our group had a lower rate of adverse events.

DOI

10.3906/sag-1004-783

Keywords

Chronic myeloid leukemia, imatinib, response, survival

First Page

31

Last Page

38

Download

Share

COinS